Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-RGD PET/CT to Predict Apatinib Efficacy in Malignancies
NCT03384511Phase 4Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), non-small cell lung cancer (NSCLC), esophageal cancer and 3 more, sponsored by Shandong Cancer Hospital. Primary endpoint: Tumor response defined by RECIST criteria at 1 month. Started Sep 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)non-small cell lung cancer (NSCLC)esophageal cancerbreast cancerovarian cancer
Beyond the preview
Go deeper on NCT03384511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384511.